OVID News and Press, Ovid Therapeutics Inc. From 06/17/24

A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...

Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy endpoints all with p-values ≤ 0.008 Takeda’s Skyway st...

2024-05-28 13:09:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors should focus on these penny stocks to sell in May to avoid potential losses. While more affordable and often appealing to investors with limited capital, Penny stocks can also car...

2024-05-20 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I’m not talking about having an aggressive mistrust toward such enterpris...

2024-05-14 13:54:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ovid Therapeutics (NASDAQ: OVID ) just reported results for the first quarter of 2024. Ovid Therapeutics reported earnings per share of -17 cents. This was above the analy...

2024-05-14 10:32:00 ET More on Ovid Therapeutics Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 Ovid Therapeutics gains on bullish view at Wedbush Seeking Alpha’s Quant Rating on Ovid Therapeutics Historical earnings data for...

Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal year A Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete; topline sa...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by rare epilepsies and brain conditions, today announced that management will par...

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...